Enliven Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Enliven Therapeutics, Inc. carries a market capitalization of 4.25B, placing it among publicly traded companies globally. Its enterprise value stands at 2.82B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.25B |
| Enterprise Value | 2.82B |
Share Statistics
Enliven Therapeutics, Inc. currently has 73.25M shares outstanding.
| Shares Outstanding | 73.25M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 4.15 |
| P/TBV Ratio | 4.15 |
| P/FCF Ratio | -48.08 |
| P/OCF Ratio | -48.01 |
Financial Position
Enliven Therapeutics, Inc. maintains a current ratio of 64.07, meaning it holds 64.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 64.07 |
| Quick Ratio | 63.21 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -15.31 |
| Return on Assets (ROA) | -14.98 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Enliven Therapeutics, Inc.'s stock has gained approximately 201.44304% over the past 52 weeks. The 50-day moving average sits at 50.40, while the 200-day moving average is 34.71.
| Beta (5Y) | N/A |
| 52-Week Price Change | 201.44304% |
| 50-Day Moving Average | 50.40 |
| 200-Day Moving Average | 34.71 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -124.28M, while operating income came in at -124.41M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -124.41M |
| Pretax Income | -105.93M |
| Net Income | -105.93M |
| EBITDA | -124.28M |
| EBIT | -124.41M |
| Earnings Per Share (EPS) | -1.67 |
Balance Sheet
Enliven Therapeutics, Inc. holds 895.16M in cash and equivalents against 597,000.00 in total debt, resulting in a net debt position of -135.50M. Total book value stands at 895.15M, with working capital of 893.18M providing operational flexibility.
| Cash & Cash Equivalents | 895.16M |
| Total Debt | 597,000.00 |
| Net Debt | -135.50M |
| Equity (Book Value) | 895.15M |
| Book Value Per Share | 12.22 |
| Working Capital | 893.18M |
Cash Flow
Enliven Therapeutics, Inc. produced -66.94M in operating cash flow over the past twelve months. After subtracting -98,000.00 in capital expenditures, free cash flow totaled -67.04M - equivalent to -1.06 per share.
| Operating Cash Flow | -66.94M |
| Capital Expenditures | -98,000.00 |
| Free Cash Flow | -67.04M |
| FCF Per Share | -1.06 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -12.74 |
| FCF Yield | -2.08 |
Stock Splits
Enliven Therapeutics, Inc.'s most recent stock split took place on February 24, 2023 with a 4:1 split ratio.
| Last Split Date | 2/24/2023 |
| Split Ratio | 4:1 |
Scores
Enliven Therapeutics, Inc. posts an Altman Z-Score of 148.08, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 148.08 |